BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18472237)

  • 1. p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.
    Oridate N; Homma A; Higuchi E; Suzuki F; Hatakeyama H; Mizumachi T; Furusawa J; Taki S; Furuta Y; Fukuda S
    Auris Nasus Larynx; 2009 Feb; 36(1):57-63. PubMed ID: 18472237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
    Higuchi E; Oridate N; Homma A; Suzuki F; Atago Y; Nagahashi T; Furuta Y; Fukuda S
    Head Neck; 2007 Oct; 29(10):940-7. PubMed ID: 17563903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
    Lavertu P; Adelstein DJ; Myles J; Secic M
    Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
    Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
    Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
    Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
    Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
    Kovács AF; Mose S; Böttcher HD; Bitter K
    Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas.
    Sakashita T; Homma A; Suzuki S; Hatakeyama H; Kano S; Mizumachi T; Oridate N; Fukuda S
    Acta Otolaryngol; 2013 Sep; 133(9):984-91. PubMed ID: 23692432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
    Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
    J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer.
    Sauter ER; Ridge JA; Litwin S; Langer CJ
    Clin Cancer Res; 1995 Nov; 1(11):1407-12. PubMed ID: 9815938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases.
    Carlos de Vicente J; Junquera Gutiérrez LM; Zapatero AH; Fresno Forcelledo MF; Hernández-Vallejo G; López Arranz JS
    Head Neck; 2004 Jan; 26(1):22-30. PubMed ID: 14724903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
    Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
    Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.